Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Board Changes and Corporate Update

1 Apr 2016 12:44

RNS Number : 9216T
West African Minerals Corporation
01 April 2016
 

For immediate release

1 April 2016

West African Minerals Corporation

("West African" or the "Company")

 

Board changes and corporate update

 

The Board of the Company announces that on 31 March 2016, Brad Mills informed the Company that he had resigned as Chairman of the Board of the Company with immediate effect. Gerard Holden, an existing Non-Executive Director, has been appointed Chairman. Brad Mills will remain as a Non-Executive Director of the Company.

 

The Board of the Company is now as follows:

 

Gerard Holden

Chairman

James Mellon

Non-Executive Director

Andrew Gutmann

Non-Executive Director

Willy Simon

Non-Executive Director

Brad Mills

Non-Executive Director

 

As previously announced on 27 February 2015, the Company had appointed Plinian Capital Limited as operator of the Company's Cameroon projects at a total annual cost of US$160,000 (equivalent to approximately £103,000) for an initial term of 12 months ("Operator Agreement"). Brad Mills, who is also the controlling shareholder of Plinian Capital Limited, informed the Company yesterday that the Operator Agreement would also terminate with effect from 31 March 2016.

 

For further information contact:

West African Minerals Corporation

Gerard Holden

 

+44 (0) 7785 503 593

 

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Michael Cornish

 

+44 (0)20 7628 3396

SP Angel Corporate Finance LLP (Broker)

Ewan Leggat

 

+44 (0) 20 3470 0500

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSLSFILIIR
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.